Conveniently scheduled in the mornings during the week of December 6, 2010, these programs are designed to keep you up to date on the latest developments impacting your business. You are invited to attend one, some, or all of the sessions.
Topics to be covered include:
- What Every Corporate Counsel Should Know About Executory Contracts in Bankruptcy
- Dealer and Distributor Terminations and Litigation
- Economic Uncertainty and Your Credit Facilities
- What Every Corporate Counsel Should Know About Attorney-Client Privilege and Work Product
- Update on Dodd-Frank Act Executive Compensation and Corporate Governance Provisions
- What Every Corporate Counsel Should Know About Antitrust
- Emerging Issues in Intellectual Property
- What Every General Counsel Should Know About Executive Compensation Tax Issues
- What Every Corporate Counsel Should Know About Environmental Enforcement Trends and Emerging Environmental Regulations
- Ethics 2010
Year in Review: A Continuing Legal Education Program Series is part of the Foley Executive Briefing Series.
People
Related Insights
December 4, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
December 4, 2025
Foley Viewpoints
Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift
Foley & Lardner, Protiviti and SS&C Intralinks recently hosted an event in Foley’s Silicon Valley office at Palo Alto Center. Moderated by Foley partner Louis Lehot, the session titled "Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shifts," brought together industry leaders: JD Fay (ex-CFO, Matterport, de-SPAC’d and then sold to CoStar Group), Dan Angus (Managing Director, Nasdaq), and Andrea Vardaro Thomas (Managing Director, Protiviti). Their combined experience provided a roadmap for companies facing the volatile and rapidly shifting capital markets of 2026.
December 4, 2025
Foley Viewpoints
FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation
FDA’s September 2025 guidance requires detailed characterization of posttranslational modifications (PTMs), particularly glycosylation,…